Blood is still pumping in Silicon Valley.Amid the collapse of Theranos Inc. last year, investors are betting that some of the disgraced blood-testing startup’s lofty medical goals might still have a kernel of promise -- at other companies.Read the full article here.
Press inquires
pr@genalyte.com